Plasma SNORD83A as a potential biomarker for early diagnosis of non-small-cell lung cancer

2021 ◽  
Author(s):  
Kangyu Wang ◽  
Xingguo Song ◽  
Xinyi Li ◽  
Zhijun Zhang ◽  
Li Xie ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Small Cell Lung Cancer ◽  
Carcinoembryonic Antigen ◽  
Small Cell ◽  
Diagnostic Efficiency ◽  
Diagnostic Biomarker ◽  
Small Cell Lung ◽  
Healthy Donors ◽  
Nsclc Patients

Aim: This study aimed to access the efficacy of plasma small nucleolar RNAs in early diagnosis of non-small-cell lung cancer (NSCLC). Methods: SNORD83A was selected based on databases and further verified in 48 paired formalin-fixed, paraffin-embedded tissues, as well as in plasma from 150 NSCLC patients and 150 healthy donors. The diagnostic efficiency of plasma SNORD83A, as well as in combination with carcinoembryonic antigen, was determined by receiver operating characteristic analysis. Results: SNORD83A was significantly increased not only in tissues but also in plasma from NSCLC patients compared with those from healthy donors. Plasma SNORD83A was able to act as a diagnostic biomarker for NSCLC. The diagnostic efficiency of carcinoembryonic antigen was also significantly elevated for early-stage NSCLC when combined with SNORD83A. Conclusion: SNORD83A can serve as a diagnostic biomarker for NSCLC.

scholarly journals Permissible Outcomes of Lobe-Specific Lymph Node Dissection for Elevated Carcinoembryonic Antigen in Non-Small Cell Lung Cancer

Medicina ◽  
2021 ◽  
Vol 57 (12) ◽  
pp. 1365
Author(s):  
Hiroaki Kuroda ◽  
Junji Ichinose ◽  
Katsuhiro Masago ◽  
Yusuke Takahashi ◽  
Takeo Nakada ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Carcinoembryonic Antigen ◽  
Cell Lung Cancer ◽  
Early Stage ◽  
Disease Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Nodal Dissection ◽  
Nsclc Patients

Background and Objectives: Lobe-specific nodal dissection (L-SND) is currently acceptable for the dissection of early-stage non-small cell lung cancer (NSCLC) but not for cancers of more advanced clinical stages. We aimed to assess the efficacy of L-SND, compared to systemic nodal dissection (SND). Materials and Methods: We retrospectively collected the clinical data of patients with carcinoembryonic antigen (CEA) abnormality who underwent complete resection of NSCLC via lobectomy or more in addition to either SND or L-SND at two cancer-specific institutions from January 2006 to December 2017. Results: A total of 799 patients, including 265 patients who underwent SND and 534 patients who underwent L-SND, were included. On multivariate analysis, thoracotomy, more than lobectomy, cN1-2, advanced pathological stage, adjuvant treatment, and EGFR or ALK were strongly associated with SND. No significant differences were found in overall survival, disease-free survival, and overtime survival after propensity adjustment (p = 0.09, p = 0.11, and p = 0.50, respectively). There were no significant differences in local (p = 0.16), regional (p = 0.72), or distant (p = 0.39) tumor recurrence between the two groups. Conclusions: SND did not improve the prognosis of NSCLC patients with CEA abnormality. Complete pulmonary resection via L-SND seems useful for NSCLC patients with CEA abnormality.

Long intergenic noncoding RNA LINC00173 as a potential serum biomarker for diagnosis of non-small-cell lung cancer

2020 ◽  
Vol 29 (4) ◽  
pp. 441-451 ◽  
Author(s):  
Qian Yang ◽  
Shan Kong ◽  
Ming Zheng ◽  
Yuelan Hong ◽  
Jing Sun ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Differentially Expressed ◽  
Diagnostic Biomarker ◽  
Small Cell Lung ◽  
Qrt Pcr ◽  
Nsclc Patients ◽  
Combined Detection

BACKGROUND: Long intergenic non-coding RNA (lincRNA) belongs to a special type of RNA that is unable to encode proteins but has been proved to play a role in gene regulation and differentially expressed in various malignant tumors. OBJECTIVE: In this study, we aimed to identify whether lincRNA LINC00173 was differentially expressed in non-small-cell lung cancer (NSCLC) and whether it could serve as a potential diagnostic biomarker. METHODS: The quantification real-time quantitative polymerase chain reaction (qRT-PCR) was used to detect the expression of LINC00173 in serum and cultured cells. For large sample analysis, the lncRNA expression matrix in TCGA database were generated via R software. To evaluate the diagnostic performance of serum LINC00173, the receiver operating characteristic (ROC) curve was used. RESULTS: The qRT-PCR analysis showed that the serum LINC00173 expression level in 108 NSCLC patients was higher than that in 91 healthy donors and 55 patients with benign pulmonary disease (BPD). And the area under the curve (AUC) of serum LINC00173 was 0.809 for the diagnosis of NSCLC (95% CI: 0.750–0.868, p< 0.001), 0.670 for BPD (95% CI: 0.584–0.756, P< 0.001), and 0.730 for small-cell lung cancer (SCLC, 95% CI: 0.636–0.825, P< 0.001). Besides, we established a diagnostic model of combined detection of LINC00173, CEA and Cyfra21-1, and found that combined detection of these indicators significantly improved the diagnostic efficiency. Analysis of the Clinicopathological parameters showed that high LINC00173 expression was correlated with histological typing of tumor, tumor metastasis and serum Cyfra21-1 levels. In addition, serum LINC00173 expression decreased in patients who received chemotherapy and rebound in recurrent NSCLC patients. CONCLUSION: Serum LINC00173 may prove to be a potential non-invasive auxiliary diagnostic biomarker for NSCLC patients.

scholarly journals Circulating CD15+LOX-1+ PMN-MDSCs are a potential biomarker for the early diagnosis of non-small cell lung cancer

2020 ◽  
Author(s):  
Xinyu Tian ◽  
Ting Wang ◽  
Qisi Zheng ◽  
Yue Tao ◽  
Lei Dai ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Roc Curve ◽  
Small Cell ◽  
Cytokeratin 19 ◽  
Small Cell Lung ◽  
Potential Biomarker ◽  
Nsclc Patients

Aims: Non-small-cell lung cancer (NSCLC) is the most common clinical lung cancer. Polymorphonuclear-myeloid derived suppressor cells (PMN-MDSCs), which are the major population of MDSCs, are involved in NSCLC progression. Recently, it was found that lectin-type oxidized LDL receptor 1 (LOX-1) could identify humsn PMN-MDSCs. However, the role of CD15+LOX-1+ PMN-MDSCs in NSCLC early diagnosis has not been revealed. Here, we tried to confirm the application of the newly-identified CD15+LOX-1+ PMN-MDSCs in the early diagnosis of NSCLC. Methods: Flow cytometry (FCM) was used to detect the proportion of CD15+LOX-1+ PMN-MDSCs in the peripheral blood (PB) of healthy controls (HC) and NSCLC patients. The correlation of CD15+LOX-1+ PMN-MDSC frequency with levels of cytokeratin 19-fragments (CYFRA21-1), carcinoembryonic antigen (CEA), and carbohydrate antigen 125 (CA125) was analyzed. Receiver operating characteristic (ROC) curve was used to estimate the diagnostic efficacy of CD15+LOX-1+ PMN-MDSCs for NSCLC. Additionally, the association of CD15+LOX-1+ PMN-MDSC frequency with NSCLC prognosis/recurrence after surgery was explored. Results: The proportion of CD15+LOX-1+ PMN-MDSCs increased in PB of NSCLC patients. CD15+LOX-1+ PMN-MDSC proportion was positively correlated with levels of CEA and CYFRA21-1. The area under the ROC curve (AUC) of PMN-MDSC percentage was higher than CYFRA21-1, CEA and CA125. The proportion of CD15+LOX-1+ PMN-MDSCs decreased in patients after surgery. The frequency of CD15+LOX-1+ PMN-MDSCs was lower in NSCLC patients without recurrence compared to those with recurrence after surgery. Conclusions: Circulating CD15+LOX-1+ PMN-MDSCs are a potential diagnostic marker for NSCLC, and are associated with NSCLC prognosis and recurrence after surgery.

scholarly journals Hsa_Circ_0054284 Functions as a Tumor Suppressor via The Mir-18a-3p/TIMP2 Pathway in Non–Small-Cell Lung Cancer

2021 ◽  
Author(s):  
Zhexuan Xu ◽  
Chunya Lu ◽  
Guojun Zhang
Keyword(s):  
Lung Cancer ◽  
Early Diagnosis ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Expression Patterns ◽  
Small Cell ◽  
Small Cell Lung ◽  
Pcr Assay ◽  
Qrt Pcr ◽  
Nsclc Patients

Abstract Background: Non-small cell lung cancer (NSCLC) patients are basically at an advanced stage once diagnosed. In this study, our aimed to identify a new biomarker for early diagnosis of NSCLC.Methods and materials: CircRNA array analysis was designed to study the expression patterns of circRNAs in three pairs of NSCLC tissues. The expression of hsa_circ_0054284 were detected in 30 paired NSCLC tissues and adjacent normal tissues by qRT-PCR assay. A549 and H520 cells were transfected with overexpression vector of hsa_circ_0054284 and negative control. CCK-8, transwell invasion and Cell apoptosis assay were using to explore the internal relationship among the hsa_circ_0054284, miR-18a-3p and TIMP2. TIMP2 expression level was detected by qRT-PCR assay and western blotting analysis.Results: Hsa-circ-0054284 overexpression suppressed A549/H520 cell proliferation and invasion and promoted apoptosis via downregulation of miR-18a-3p and targeting TIMP2. This might be one of the possible mechanisms, which hsa-circ-0054284 plays in NSCLC.Conclusion: The current study provides novel insights into the circRNA-related ceRNA network in NSCLC and the hsa-circ-0054284 biomarkers may be Early diagnosis in NSCLC patients.

scholarly journals Biomarkers and Gene Signatures to Predict Durable Response to Pembrolizumab in Non-Small Cell Lung Cancer

Cancers ◽  
2021 ◽  
Vol 13 (15) ◽  
pp. 3828
Author(s):  
Anello Marcello Poma ◽  
Rossella Bruno ◽  
Iacopo Pietrini ◽  
Greta Alì ◽  
Giulia Pasquini ◽  
...  
Keyword(s):  
Lung Cancer ◽  
T Cells ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Immune Cell ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Durable Response ◽  
Nsclc Patients

Pembrolizumab has been approved as first-line treatment for advanced Non-small cell lung cancer (NSCLC) patients with tumors expressing PD-L1 and in the absence of other targetable alterations. However, not all patients that meet these criteria have a durable benefit. In this monocentric study, we aimed at refining the selection of patients based on the expression of immune genes. Forty-six consecutive advanced NSCLC patients treated with pembrolizumab in first-line setting were enrolled. The expression levels of 770 genes involved in the regulation of the immune system was analysed by the nanoString system. PD-L1 expression was evaluated by immunohistochemistry. Patients with durable clinical benefit had a greater infiltration of cytotoxic cells, exhausted CD8, B-cells, CD45, T-cells, CD8 T-cells and NK cells. Immune cell scores such as CD8 T-cell and NK cell were good predictors of durable response with an AUC of 0.82. Among the immune cell markers, XCL1/2 showed the better performance in predicting durable benefit to pembrolizumab, with an AUC of 0.85. Additionally, CD8A, CD8B and EOMES showed a high specificity (>0.86) in identifying patients with a good response to treatment. In the same series, PD-L1 expression levels had an AUC of 0.61. The characterization of tumor microenvironment, even with the use of single markers, can improve patients’ selection for pembrolizumab treatment.

Sign in / Sign up

Export Citation Format

Share Document